SPECIAL REPORT
Improving the Diagnosis and Management of Diabetes Advances in C-Peptide Testing Improve Diabetes Type Identification A Healthcare Problem That Is Growing for Patients and For Society Living with a Long-Term Challenge Getting to Grips with a Progressive Condition Understanding and Looking Forward
Sponsored by
Published by Global Business Media
We take diabetes personally The global impact of Diabetes is immense Ortho Clinical Diagnostics understands the growing prevalence of diabetes and is dedicated to confronting diabetes’ real impact to patient quality of life and to health care economics. Ortho’s comprehensive diabetes menu is available on VITROSŽ Immunoassay and Integrated Systems: trustworthy, reliable results, Ortho service and support, and standardized performance across the family of systems.
Please visit www.orthoclinicaldiagnostics.com PR-04048
SPECIAL REPORT
Improving the Diagnosis and Management of Diabetes Advances in C-Peptide Testing Improve Diabetes Type Identification
SPECIAL REPORT: IMPROVING THE DIAGNOSIS AND MANAGEMENT OF DIABETES
Contents
A Healthcare Problem That Is Growing for Patients and For Society Living with a Long-Term Challenge Getting to Grips with a Progressive Condition Understanding and Looking Forward
Foreword
2
John Hancock, Editor
Advances in C-Peptide Testing Improve Diabetes Type Identification
3
Ortho Clinical Diagnostics Sponsored by
Published by Global Business Media
Published by Global Business Media Global Business Media Limited 62 The Street Ashtead Surrey KT21 1AT United Kingdom Switchboard: +44 (0)1737 850 939 Fax: +44 (0)1737 851 952 Email: info@globalbusinessmedia.org Website: www.globalbusinessmedia.org Publisher Kevin Bell Business Development Director Marie-Anne Brooks Editor John Hancock Senior Project Manager Steve Banks Advertising Executives Michael McCarthy Abigail Coombes Production Manager Paul Davies For further information visit: www.globalbusinessmedia.org The opinions and views expressed in the editorial content in this publication are those of the authors alone and do not necessarily represent the views of any organisation with which they may be associated. Material in advertisements and promotional features may be considered to represent the views of the advertisers and promoters. The views and opinions expressed in this publication do not necessarily express the views of the Publishers or the Editor. While every care has been taken in the preparation of this publication, neither the Publishers nor the Editor are responsible for such opinions and views or for any inaccuracies in the articles. Š 2018. The entire contents of this publication are protected by copyright. Full details are available from the Publishers. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical photocopying, recording or otherwise, without the prior permission of the copyright owner.
Introduction The Role of C-peptide Testing Clinical Utility of C-Peptide Testing in Diabetes Diagnosis and Patient Management Distinguishing Between Type 1 and Type 2 Diabetes The Role of VITROSÂŽ C-peptide
A Healthcare Problem That Is 6 Growing for Patients and For Society John Hancock, Editor
Symptoms of Diabetes Prevalence of Diabetes Living with Diabetes
Living with a Long-Term Challenge
8
Camilla Slade, Staff Writer
The Cost Burden of Diabetes Causes of Diabetes People at Risk from Diabetes Co-Morbidities with Diabetes A Global and Lifelong Issue
Getting to Grips with a Progressive Condition
10
Peter Dunwell, Medical Correspondent
Diagnosing Diabetes Treating Diabetes
Understanding and Looking Forward
12
John Hancock, Editor
A Complex Condition Looking to the Future Summary
References 14
WWW.HOSPITALREPORTS.EU | 1
SPECIAL REPORT: IMPROVING THE DIAGNOSIS AND MANAGEMENT OF DIABETES
Foreword
S
OME PROJECTIONS would have diabetes
plus, of course, how it affects the most important
as the number one healthcare issue of our
person, the patient. Following that, Camilla Slade
times. Whether that’s true or only true of developed
tackles one of the most important factors about
societies, it is a major problem for those who have
diabetes - its long-term nature and what that costs
to live with it and for the healthcare systems that
patients and healthcare systems.
have to treat and manage the condition in ever
In any health issue, early diagnosis will support
increasing numbers of patients. In that context,
a better outcome and Peter Dunwell takes that
the title of this paper, ‘Improving the Diagnosis and
premise to establish how better outcomes can
Management of Diabetes’, is particularly apposite.
be achieved and some of the technologies that
In order to put the main purpose into context, we
will help to get there. Finally, we round-up on
have looked at the condition in question to consider
diabetes as well as some of the complexities and
why it is such a challenge and what might be done
co-morbidities that typify it. We also take a look
to address that challenge.
into the future with some of the research programs
Our first article, from Ortho Clinical Diagnostics,
and improved management processes that are
looks at a process of tests or assays that will
helping to prevent type 2 diabetes by bringing
offer significant help when clinicians are trying
about lifestyle changes and/or more effectively
to determine the exact nature of their patient’s
treat diabetes of all types with new ideas or new
diabetes in order to ensure the best treatment. Then
applications of current drugs and processes.
we look further into diabetes, some ideas on how to identify and diagnose it sooner rather than later, its impact at a global and healthcare system level
John Hancock Editor
John Hancock, an Editor of Hospital Reports Europe, has worked in healthcare reporting and review for many years. A journalist for nearly 30 years, John has written and edited articles, papers and books on a range of medical and management topics. Subjects have included management of long-term conditions, elective and non-elective surgery, wound management, complex health issues, Schizophrenia, health risks of travel, local health management and NHS management.
2 | WWW.HOSPITALREPORTSEUROPE.EU
SPECIAL REPORT: IMPROVING THE DIAGNOSIS AND MANAGEMENT OF DIABETES
Advances in C-Peptide Testing Improve Diabetes Type Identification Ortho Clinical Diagnostics
O
VER 422 million people are affected by diabetes globally – half are undiagnosed. The global cost of diabetes is now $825 billion dollars annually and that cost will increase. It is projected that 700 million adults worldwide will have the disease by 2025.a, b For the millions of people affected by diabetes, the toll on their daily life is undeniable. From diagnosis to monitoring and managing complications – diabetes is a complex and diverse disease demanding life-long collaboration between patients, their clinicians and laboratories. The role of the laboratory is vital to confronting diabetes’ real impact to patient quality of life and to health care economics. 75% of medical decisions are based, in great part, on the outcome of laboratory tests.c As dedicated members of the diagnostic team, the laboratory staff works hard to deliver accurate, reliable results for clinicians and their patients the first time - and every time. Glucose and HbA1c are the mainstays of diabetes diagnosis and management. Other tests run to aid with diabetes diagnosis and monitoring include: Beta-Hydroxybutyrate, Glycated Serum Protein, BUN/Urea, Creatinine, Microalbumin, lipid panel (total, LDL and HDL cholesterol, and Triglycerides), liver function panel, Insulin and C-peptide. There are often co-morbidities that need to be monitored and managed for patients who have been diagnosed with diabetes. Optimal care and treatment of diabetic patients demands a broad menu covering not just diabetes, but complications, such as cardiovascular disease, nephropathy, nonalcoholic fatty liver disease (NAFLD). Ortho Clinical Diagnostics has comprehensive panels in these areas to help the laboratory serve clinicians and patients who struggle with these complex treatment situations.
The Role of C-peptide Testing C-peptide may become a more widely run test to help lead to improved patient care as more studies are completed and researchers begin to better understand the role in diabetes.
The role of the lab is vital Every patient depends on C-peptide is cleaved from proinsulin and secreted from pancreatic beta cells at equimolar amounts to endogenous insulin. While insulin plays a very important role in regulating blood glucose levels and protein and fat metabolism, C-peptide is widely applied to evaluate pancreatic beta cell function and secretion of insulin. C-peptide is a preferred biomarker for assessing beta cell function and insulin production. While insulin is extensively metabolized in the liver by firstpass metabolism, C-peptide is mainly cleared in peripheral circulation; thus, the half-life of C-peptide is much longer than insulin (20-30 minutes vs. 3-5 minutes), allowing a wider test window for the analyte.d,e C-peptide and Insulin are secreted in equimolar amounts, therefore, either can be used to assess beta cell function and insulin production. However, in patients treated with exogenous insulin, testing C-peptide has an advantage due to the lack of cross-reactivity with therapeutic insulin or insulin analogs.
Clinical Utility of C-Peptide Testing in Diabetes Diagnosis and Patient Management The scientific understanding of diabetes has greatly improved in the past few decades. The disease classification has evolved from agebased, to insulin-dependency-based, to the present definition. The current classification of diabetes by both the American Diabetes Association and the World Health Organization is based on etiopathogenesis, the existence of beta cell autoimmune antibodies. The two major types of diabetes are type 1 diabetes, characterized by beta cell destruction due to autoimmune disorder; and type 2 diabetes, characterized by no or inadequate response to insulin. In clinical practice, the distinction between type 1 and type 2 diabetes is not always straightforward, especially when the disease is first diagnosed. C-peptide has been recommended as a diabetes classification tool. Many studies have demonstrated that C-peptide performs better than age or BMI as an indicator of diabetes.f
reliable diagnostic tests to improve outcomes over the course of this lifelong condition. Ortho helps you deliver accurate, reliable results.
We take diabetes personally
PR-04051
ORTHOCLINICALDIAGNOSTICS.COM
WWW.HOSPITALREPORTS.EU| 3
SPECIAL REPORT: IMPROVING THE DIAGNOSIS AND MANAGEMENT OF DIABETES
Diabetes is a complex and diverse disease demanding life-long collaboration between patients, their clinicians and laboratories
Serum C-peptide can be measured in three ways – randomly, after fasting, and after glucagon stimulation. A study has shown that all three tests, random C-peptide in particular, correlate with clinical types of diabetes with significant differences (P<0.0001), therefore providing powerful discrimination value between type 1 and type 2 diabetes.g The Diabetes Control and Complications Trial (DCCT), a landmark study that established the benefits of intensive treatment and a lower HbA1c in the prevention of diabetes complications, used stimulated C-peptide to identify type 1 diabetes patients.h
Distinguishing Between Type 1 and Type 2 Diabetes However, since there is substantial overlap between C-peptide levels in type 1 and type 2 diabetes at the early stages of the disease, the testing result must be interpreted with caution. NICE guidelines for diabetes diagnosis and management recommend that clinicians consider measuring C peptide after initial presentation, if there is difficulty distinguishing type 1 diabetes from other types. C-peptide concentration has greater discriminative value the longer the interval between initial presentations, because beta cell function decreases rapidly with increasing disease duration, as do insulin and C-peptide levels.i In addition to differential diagnosis of type 1 and type 2 diabetes, C-peptide also helps identify patients with monogenic beta cell disorders, such as maturity-onset diabetes of the young (MODY). Patients with MODY are often misdiagnosed with type 1 diabetes due to the young age of onset (20-40 years of age), and therefore treated with insulin. However, these patients have continued endogenous insulin secretion. Genetic testing
4 |WWW.HOSPITALREPORTS.EU
revealed that the most frequent causes of MODY are mutations in the genes HNF1A, HNF4A, and the glucokinase enzyme (more than 60% of cases). Strictly following the current guidelines for selecting subjects for genetic testing confers low sensitivity and may lead screeners to miss more than half of MODY patients.j It was recommended that all patients with persistent C-peptide (serum level >=0.2 nmol/L, 3 years after diagnosis for type 1 diabetes) and diagnosed age up to 30 should be considered for MODY genetic testing.k About 10-15% of adult onset diabetes cases are autoimmune diabetes, i.e. latent autoimmune diabetes (LADA).l These patients initially may not be insulin-dependent and clinically are difficult to distinguish from type 2 diabetes patients, but test positive for the autoimmune antibodies and progress to become insulin-dependent later. Although the pathogenesis of LADA remains unclear, early diagnosis of LADA is very important for the patients, because early intervention such as insulin use could help preserve beta cells, improve glycemic control, and reduce the risk of diabetes complications. In clinical practice, C-peptide can be used as an initial screening assay of LADA in adult onset diabetes patients. One study showed that the mean random C-peptide level in the LADA patients was 1.0 Âą 0.2 ng/mL, with 5.1Âą 0.4 ng/mL in the type 2 diabetes group. Therefore, to identify LADA patients, starting with C-peptide testing and then testing for autoimmune antibodies among patients with normal or low C-peptide levels at the onset of diabetes, could be a more cost-efficient and practical way to establish or exclude the diagnosis of LADAm In addition to the diagnostic value, increasing evidence has demonstrated that C-peptide levels
SPECIAL REPORT: IMPROVING THE DIAGNOSIS AND MANAGEMENT OF DIABETES
VITROS® C-peptide Assay characteristics Time to Sample Calibration Calibrator Reagent Reagent Reporting Recommended first result volume interval levels/reps on-board type range sample type stability 27 minutes 40 μL Lot change 3 levels x 1 Up to Liquid 0.050-30.0 Serum, plasma or every replicate 12 weeks ready ng/mL (EDTA and 28 days to use Lithium heparin)
could predict future glycemic control and diabetes complications. For type 1 diabetes patients, the DCCT study showed that patients with a baseline mixed-meal stimulated C-peptide of > 0.2 nmol/L had better glycemic control and reduced incidences of retinopathy and nephropathy.5 Association between high C-peptide levels and occurrence of macrovascular complications and metabolic control disorders has been confirmed by researchers in type 2 diabetes, however, there is controversy regarding associations between C-peptide and microvascular lesions.n,o,p
The Role of VITROS® C-peptide Ortho Clinical Diagnostics has recently added VITROS® C-peptide to an already extensive diabetes and diabetes comorbidities management menu. “Our goal at Ortho is to provide the broad range of tools health care
providers need to monitor and manage complex metabolic diseases and conditions like diabetes,” said Robert Yates, Ortho’s chief operating officer. “Adding C-peptide to Ortho’s VITROS® menu demonstrates our continued commitment to innovation that helps our customers achieve their goals.” Because Diabetes is managed as a chronic, lifelong condition with several significant comorbidities, laboratories need a partner that supports the continuum of Diabetes care. In addition to tests that make a difference in how your doctors treat and patients meet their diabetes management goals, Ortho provides laboratories with consulting services and tools to help face the challenges of increased testing volume due to escalating chronic disease rates and an aging population. That’s the power of partnership.
References: a. Diabetes [Internet]. World Health Organization. World Health Organization; [cited 2017Jul24]. Available from:
http://www.who.int/mediacentre/factsheets/fs312/en/ b. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants The Lancet, Volume 387, Issue 10027, 1513 – 1530 c. Rohr et al. The Value of In Vitro Diagnostic Testing in Medical Practice: A Status Report. PLoS One. 2016:11 d. Burtis C, Bruns D. Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics, 7th ed. Saunders Co; 612-616, 2015. e. Rubenstein A, Clark J et al. Secretion of proinsulin C-peptide by pancreatic beta cells and its circulation in blood. Nature 1969; 224: 697-699. https://www.nature.com/articles/224697a0 f. Thunander M, Tirn C et al. Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden. European Journal of Endocrinology 2012; 166: 1021-1029 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361790/ g. Berger B, Stenstrom G et al. Random C-peptide in the classification of diabetes. Scandinavian Journal of Clinical and Laboratory Investigation 2000; 60: 687-693 https://www.ncbi.nlm.nih.gov/pubmed/11218151# h. Steffes MW, Jackson M et al. β-Cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003; 26: 832-836 http://care.diabetesjournals.org/content/diacare/26/3/832.full.pdf i. Diabetes (type 1 and type 2) in children and young people: diagnosis and management. NICE guideline, updated 2016 https://www.nice.org.uk/guidance/ng18/chapter/1-Recommendations#diagnosis j. Shields BM et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010; 53: 2504-2508 https://www.ncbi.nlm.nih.gov/pubmed/20499044 k. Thanabalasingham G et al. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care 2012; 35: 1206-1212 https://www.ncbi.nlm.nih.gov/pubmed/22432108 l. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (Latent Autoimmune Diabetes of the Adult) Diabetes care 2001; 24: 1460-1467 http://care.diabetesjournals.org/content/diacare/24/8/1460.full.pdf m. Bell DS, Ovalle F. The role of C-peptide levels in screening for latent autoimmune diabetes in adults. American Journal of Therapeutics 2004; 11: 308-311. https://www.ncbi.nlm.nih.gov/pubmed/15266224 n. Bo S et al. Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetologica 2000; 37: 125-129. https://www.ncbi.nlm.nih.gov/pubmed/11277312 o. Ramazan Sari and Mustafa Kemal Balci. Relationship between C peptide and chronic complications in type-2 diabetes mellitus. Journal of the National Medical Association 2005; 97:1113-1118 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575980/pdf/jnma00189-0067.pdf p. Bo S et al. C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up European Journal of Endocrinology 2012; 167: 173-180. http://www.eje-online.org/content/167/2/173.full
The power of partnership Labs need a partner that supports the continuum of Diabetes care. Ortho covers your patients as their disease evolves.
We take diabetes personally
PR-04050
ORTHOCLINICALDIAGNOSTICS.COM
WWW.HOSPITALREPORTS.EU| 5
SPECIAL REPORT: IMPROVING THE DIAGNOSIS AND MANAGEMENT OF DIABETES
A Healthcare Problem That Is Growing for Patients and For Society John Hancock, Editor Diabetes; what it is, who has it and how it impacts on the lives of those with it
The main thing about early diabetes is that you can have abnormal blood sugar for quite some time and be fairly asymptomatic
B
EFORE LAUNCHING into the meat of this Report, it might be useful to reprise the condition in question. “Diabetes is a serious, lifelong condition where [a patient’s] blood glucose level is too high. There are two main types, Type 1and Type 2. They’re different conditions, but they’re both serious. There are some other rarer types of diabetes too.” Diabetes UK1 sums it up succinctly and mentions the two main types. With type 1 diabetes, the body stops producing insulin when the pancreas is attacked by the body’s immune system and about 10% of diabetes cases are of this type. In a patient with type 2 diabetes the body does not produce enough insulin to support normal functions or has insulin resistance, and about 90% of diabetes cases are of this type. In either case, the body is unable to or has limited ability to process sugar. The full name for the condition is Diabetes Mellitus. Of the ‘rarer’ types, probably Gestational Diabetes, which can occur during pregnancy, is the more common.
Symptoms of Diabetes Diabetes.co.uk 2 identifies the three main symptoms of diabetes as polyuria (the need to urinate frequently); polydipsia (increased thirst and fluid intake); and polyphagia (increased appetite). There are, of course, other symptoms including tiredness, blurred vision, slow healing of cuts and bruises, weight loss – type 1 – despite the polyphagia, a fruity odour to the breath – also type 1 – and numbness or tingling in hands and/ or feet – type 2. The symptoms are similar for both types and, more importantly, can be so mild at the start, particularly of type 2 diabetes, as to either go unnoticed or delay diagnosis. “The main thing about early diabetes is that you can have abnormal blood sugar for quite some time and be fairly asymptomatic,” Dr Susan Spratt, an endocrinologist and assistant professor of 6 |WWW.HOSPITALREPORTS.EU
medicine at Duke University School of Medicine, told CBS News3. Gestational Diabetes often presents no symptoms, so screening of pregnant women, especially if they are in an ‘at risk’ group, is essential. Especially with type 2 diabetes, the mild symptoms can be passed off as the result of long hours working in a stressful job, and/or if the patient is less than careful about their condition. It might be as long as ten years before a proper diagnosis is made, which can have serious longterm consequences for the patient and for the healthcare system. Diabetes UK4 spells it out; “… over a long period of time, high glucose levels in your blood can seriously damage your heart, your eyes, your feet and your kidneys. These are known as the complications of diabetes.”
Prevalence of Diabetes According to Full Fact5, while it is fairly certain that there were 3.3 million people diagnosed with Diabetes in the UK in 2013/14 (a figure that is based on returns from GP practices and will have risen since then), the estimate commonly quoted that there were 590,000 undiagnosed cases in that period is less easy to verify as, “We don’t know what we don’t know.” Looking across all of Europe and even worldwide, the World Health Organisation (WHO)6 calculates that, “There are about 60 million people with diabetes in the European Region, or about 10.3% of men and 9.6% of women aged 25 years and over… Worldwide, high blood glucose kills about 3.4 million people annually. Almost 80% of these deaths occur in low- and middle-income countries, and almost half are people aged under 70 years.”WHO projects diabetes deaths will double between 2005 and 2030.” The report also highlights the startling differences across ethnic groups with type 2 diabetes six times more common in the South Asian population than in the population as a whole and up to three times more common among people of African and AfricanCaribbean origin.
SPECIAL REPORT: IMPROVING THE DIAGNOSIS AND MANAGEMENT OF DIABETES
The difference is the system VITROS® Systems ensure consistent, reliable results - the first time. Every VITROS® System is backed by Ortho’s Looking geographically rather than ethnically, Diabetes.co.uk has published a ‘Top 10’ of European diabetes rates7 which shows the UK at 43rd with just 6.6% of the population having the condition against Turkey (14.7%) and Portugal (13.1%) at the top of the list. Notwithstanding the position on a league table, it is estimated that by 2025, there will be five million people with Diabetes in the UK.
Living with Diabetes Setting aside the statistics, the key issue with diabetes is its impact on the lives of people who live with it. Unless managed very carefully, diabetes can cumulatively affect major organs such as the heart and kidneys as well as eyes, nerves and blood vessels. It is these last two, nerves and blood vessels, whose deterioration can bring diabetes related complication to almost all parts of the body. Poorly controlled, diabetes leads to complications including heart conditions and/or non-healing ulcers and, ultimately, death. In fact, life expectancy is a topic that often exercises people with diabetes and their clinicians. “There is no hard and fast answer to the question of ‘how long can I expect to live’ as a number of factors influence one’s life expectancy.
How soon diabetes was diagnosed, the progress of diabetic complications and whether one has other existing conditions will all contribute to one’s life expectancy…” says Diabetes.co.uk8. Of course, so much depends on the quality of care available in the healthcare system and the diligence with which the patient manages their condition. The same report continues to set out some of the complications that can occur (retinopathy, kidney disease and cardiovascular disease) and the associated conditions of high blood pressure and high cholesterol that might follow. However, it isn’t only the physical complications and associated conditions that can be burdensome, it’s also important to consider “The impact of diabetes on psychological well-being and quality of life.“9 That’s the title of the book on PubMed in which the authors add, “… few people understand that diabetes is a condition that cannot be simply controlled by medications and that the presence of diabetes markedly alters the lives of individuals and their families.” Further on, we’ll look at the wider impacts of diabetes, how it is treated and some new ideas to help ensure that patients with diabetes are supported sooner, appropriately and better.
Over a long period of time, high glucose levels in your blood can seriously damage your heart, your eyes, your feet and your kidneys. These are known as the complications of diabetes
Best-in-Class Service.
We take diabetes personally
PR-04049
ORTHOCLINICALDIAGNOSTICS.COM
WWW.HOSPITALREPORTS.EU| 7
SPECIAL REPORT: IMPROVING THE DIAGNOSIS AND MANAGEMENT OF DIABETES
Living with a Long-Term Challenge Camilla Slade, Staff Writer It is more than the diabetes itself with which clinicians have to deal
The disease burden related to diabetes is high and rising in every country, fueled by the global rise in the prevalence of obesity and unhealthy lifestyles
I
N 2014, diabetes was estimated to account for about 10 per cent of the UK National Health Service (NHS) budget. However, 80 per cent of that cost results from complications and, as John Hancock alluded to in the previous article, those complications are, if not wholly avoidable, certainly capable of reduction with proper management. The figures come from Diabetes UK’s ‘The cost of diabetes’ report10 which advocates a joined-up approach including the social aspect of diabetes care.
The Cost Burden of Diabetes It isn’t only the costs, although at £8 billion a year for direct costs of diabetes treatment in England, according to NHS England11, that is not insignificant; it is that burden of complications that really has to be addressed. In 2012, Diabetic Medicine12 estimated, “Diabetes cost approximately £23.7bn in the UK in 2010⁄2011: £9.8bn in direct costs (£1bn for Type 1 diabetes and £8.8bn for Type 2 diabetes) and £13.9bn in indirect costs (£0.9bn and £13bn). In real terms, the 2035⁄2036 cost is estimated at £39.8bn... Diabetes currently accounts for approximately 10% of the total health resource expenditure and is projected to account for around 17% in 2035⁄2036.” To emphasize the point, the NHS England report lists some startling statistics that will be relevant in the context of this Report and so are reproduced below in full… • I n 2012-13 there were 50,000 hospital admissions in England with a main diagnosis of diabetes. • People with diabetes are five times more likely to have heart disease or a stroke than someone without. • Diabetic retinopathy is the leading cause of preventable sight loss in people of working age in England and Wales. • Diabetes is the single most common cause of end-stage renal (kidney) failure, requiring dialysis or a transplant. • Depression is nearly twice as high among people with Type 2 diabetes than those without the condition. 8 |WWW.HOSPITALREPORTS.EU
• There were 4,974 deaths in England and Wales in 2013 for which diabetes was the underlying cause. • There were 236 avoidable deaths in England and Wales in 2013 for which diabetes was the primary cause. • In 2013 there were 23,986 premature deaths in England and Wales due to diabetes. As well as the cost to healthcare systems, the cost to families with a breadwinner unable to fulfil their role and the costs to the state to support patients unable to work as well as the impact of potential earlier mortality will add up to a significant burden on society and the economy. Estimates do not predict any reduction in the costs of diabetes (see above) and so any process that can improve the diagnosis, understanding and management of each case will reap significant returns in terms of keeping costs under control.
Causes of Diabetes While it is known that diabetes occurs when the pancreas stops making insulin (type 1) or when insulin is produced but is ineffective or in insufficient quantity (type 2), the causes of those changes are not yet fully understood. However, Nita Gandhi Forouhi and Nicholas J. Wareham in their paper ‘Epidemiology of diabetes’13 cite, “The disease burden related to diabetes is high and rising in every country, fueled by the global rise in the prevalence of obesity and unhealthy lifestyles.” as contributory lifestyle factors. That said, the lifestyle link is not associated with type 1 but with type 2 diabetes. “Type 2 diabetes usually begins with insulin resistance, a condition in which muscle, liver, and fat cells do not use insulin well. As a result, [the] body needs more insulin to help glucose enter cells. At first, the pancreas makes more insulin to keep up with the added demand. Over time, the pancreas can’t make enough insulin, and blood glucose levels rise.”14, is NIDDK’s description. Scientists think that there might be a link with viruses and/or the body’s immune system, which can attack the pancreas and trigger a complete cessation of insulin production (type 1 diabetes)
SPECIAL REPORT: IMPROVING THE DIAGNOSIS AND MANAGEMENT OF DIABETES
The role of the lab is vital Every patient depends on reliable diagnostic tests to improve outcomes over the course of this lifelong condition. Ortho helps but genetic familial predisposition is more often cited in the onset of type 1.
People at Risk from Diabetes Diabetes UK has produced a clear document ‘Diabetes risk factors’15 that categorizes who might be at risk from diabetes. Of course, anyone could get it but some groups are more likely to. As with many diseases, white people over age 40 are more at risk but Black or Asian people over 25 fall into that ‘at risk’ category, especially for type 2 diabetes. If another family member (parent or sibling) suffers from diabetes, then the risk is higher as it is if a patient has had high blood pressure or is overweight, especially around the middle. Similarly, some mental conditions such as schizophrenia, bipolar illness, depression or taking antipsychotic medication can be associated with higher risk and, for women, having had polycystic ovaries, gestational diabetes or a baby with birthweight over 10 pounds adds to the risk of developing diabetes.
Co-Morbidities with Diabetes When older people are at risk and when the onset of a condition can be associated with other factors (see above) it often leads to complex
health issues, i.e. multiple conditions that exist within one person but that each require different treatments. Most patients suffering from diabetes have co-morbidities. These can include sleep apnoea, fatty liver disease, fractures due to side effects of the condition on the bone structure, and cancer. Physician’s Weekly offers a good summation16, but these co-morbidities can be more serious than the diabetes itself, again if not well managed, and outcomes such as limb amputations are not uncommon.
A Global and Lifelong Issue Geographical17 captures the size of the challenge, “Diabetes is often thought of as a ‘western’ problem, one linked to the developed world’s overindulgence in fatty foods and chronic lack of physical activity. But with more than 400 million people affected globally, this disease is a global threat.” The other challenge is that, with diabetes being a life-long issue and with more people suffering from diabetes, it is also a cumulative problem inasmuch as, so long as the population continues to grow, and treatments continue to help patients live longer with diabetes, the condition is not going to go away in the foreseeable future.
you deliver accurate, reliable results.
We take diabetes personally
Diabetes is often thought of as a ‘western’ problem, one linked to the developed world’s overindulgence in fatty foods and chronic lack of physical activity. But with more than 400 million people affected globally, this disease is a global threat
PR-04051
ORTHOCLINICALDIAGNOSTICS.COM
WWW.HOSPITALREPORTS.EU| 9
SPECIAL REPORT: IMPROVING THE DIAGNOSIS AND MANAGEMENT OF DIABETES
Getting to Grips with a Progressive Condition Peter Dunwell, Medical Correspondent Finding, identifying and treating diabetes
Successful treatment makes all the difference to long-term health, and achieving balanced diabetes treatment can be the key to living with both type 1 and type 2 diabetes
C
URRENT TRENDS, as both John Hancock and Camilla Slade have illustrated in their articles, suggest that diabetes is a growing healthcare issue, so its diagnosis and treatment merit serious consideration.
Diagnosing Diabetes As with any diagnostic process, a clinician will wish to talk with a patient who is displaying any of the symptoms commonly associated with diabetes. Medical News Today18 offers a comprehensive and well explained list from which I’ll just include the headers: • Frequent urination; • Disproportionate thirst; • Intense hunger; • Weight gain; • Unusual weight loss; • Increased fatigue; • Irritability; • Blurred vision; • Cuts and bruises don’t heal properly or quickly; • More skin and/or yeast infections; • Itchy skin; • Gums are red and/or swollen - Gums pull away from teeth; • Frequent gum disease/infection; • Sexual dysfunction among men; •N umbness or tingling, especially in the feet and hands. Diabetes can often be detected by carrying out a urine test, which finds out whether excess glucose is present. This is normally backed up by a blood test, which measures blood glucose levels and can confirm if the cause of symptoms is diabetes.
The importance of early detection One issue with diabetes is that symptoms might not be noticed until the condition has been extant for some time. Unfortunately, any damage done will be underway during that time which, as ‘That Sugar Movement’19 explains is pre-diabetes. “Pre-diabetes is a condition when someone has higher than average blood glucose levels that 10 |WWW.HOSPITALREPORTS.EU
aren’t quite high enough to be diagnosed with type 2 diabetes… Recently published research in the British Medical Journal looked into assessing cut-off levels for pre-diabetes diagnosis, as there is considerable difference between guidelines around the globe for the lower cut-off point.” Continuing that topic, in the USA, the Department of Health has a national plan for the early detection of diabetes20 because of the number of people who are in that pre-diabetes stage, i.e. with poor sugar levels but undiagnosed. The plan explains, “Type 1 diabetes is typically detected much sooner after onset than type 2 disease because the symptoms are dramatic and the need for medical care is immediate and obvious. In contrast, the signs and symptoms of type 2 diabetes… may not be diagnosed for 7 to 10 years after the onset resulting in increased risk for complications… when the disease is finally detected… Early diagnosis of diabetes and pre-diabetes is important so that patients can begin to manage the disease early and potentially prevent or delay the serious disease complications that can decrease quality of life.” It is that final point that, with diabetes as with many conditions, is so important. Earlier diagnosis can support earlier treatment requirement which, in turn, will benefit the patient and the healthcare system’s budget. Dr. James Barnard writing for The Pritikin Longevity Center21 advocates, “If you make lifestyle changes immediately, you may be able to lower your blood sugar [glucose] to the level where you are no longer defined as having diabetes,”
Distinguishing between type 1 and type 2 diabetes One important element is to be able to distinguish between type 1 and type 2 diabetes at an early stage in the diagnosis to ensure that the correct treatment is applied as soon as possible. In that, a powerful weapon is the C-Peptide test or assay which, as WebMD22 explains, “… shows how well your body makes insulin... The test can help your doctor decide whether you need to take insulin to control your condition
SPECIAL REPORT: IMPROVING THE DIAGNOSIS AND MANAGEMENT OF DIABETES
The power of partnership Labs need a partner that supports the continuum of Diabetes care. Ortho covers your patients as their disease evolves. or to check your dosage if you already take it. Doctors can use the test whether you have type 1 diabetes, when the immune system attacks and destroys cells in the pancreas, or type 2, when your body doesn’t use insulin as well it should.” It also helps to distinguish Latent Autoimmune Diabetes in Adults (LADA) and Maturity Onset Diabetes of the Young (MODY). C-peptide is a byproduct of the beta cells in the pancreas making insulin. Diapedia23 offers a good description, “Hyperglycaemia develops when the pancreatic islets are no longer able to generate sufficient insulin to meet the requirements of the body. An insulin-insensitive individual will thus develop type 2 diabetes despite increased insulin production (‘high output failure’), whereas type 1 diabetes is associated with near-normal insulin sensitivity and ‘low-output failure’. This difference will be reflected in their levels of C-peptide at diagnosis.” PMC on NCBI ‘A Practical Review of C-Peptide Testing in Diabetes’24 sums it all up in a sentence, “Modern assays detect levels of C-peptide which can be used to guide diabetes diagnosis and management.” A good example is the C-peptide Assay offered from Ortho Clinical Diagnostics within that company’s VITROS® range.
Treating Diabetes With any health issue, treatment is important but
with a lifelong and potentially life-limiting condition such as diabetes, the quality of treatment is of critical importance. That’s because, “Successful treatment makes all the difference to longterm health, and achieving balanced diabetes treatment can be the key to living with both type 1 and type 2 diabetes.” That’s how Diabetes.co.uk opens its page on ‘Treatment for Diabetes’25. Treatment for diabetes will always have to be a bespoke process inasmuch as each patient’s condition will be individual and the number and nature of any associated conditions and co-morbidities will also need to be taken into account. In essence, it will aim to maintain blood glucose levels at as near normal level as possible in an effort to avoid complications. That’s why the page above continues to advocate a management strategy agreed by both patient and clinical care team as a first step before embarking on a treatment program that will, of necessity, include routine testing for blood sugar levels and medication (insulin injections for type 1 patients and other medications for type 2) but should also focus on diet and lifestyle matters like physical activity. Part of the program should also include regular checks with either a doctor or a specialist diabetes nurse because, given that diabetes is a progressive condition, it and the treatment it requires will change over time.
We take diabetes personally
As with any diagnostic process, a clinician will wish to talk with a patient who is displaying any of the symptoms commonly associated with diabetes
PR-04050
ORTHOCLINICALDIAGNOSTICS.COM
WWW.HOSPITALREPORTS.EU| 11
SPECIAL REPORT: IMPROVING THE DIAGNOSIS AND MANAGEMENT OF DIABETES
Understanding and Looking Forward John Hancock, Editor How diabetes works and what is being done to address the challenge that it poses
Type 2 diabetes is a common condition that causes the level of sugar (glucose) in the blood to become too high. It’s caused by problems with a chemical in the body (hormone) called insulin. It’s often linked to being overweight or inactive
A Complex Condition “Type 2 diabetes is a common condition that causes the level of sugar (glucose) in the blood to become too high. It’s caused by problems with a chemical in the body (hormone) called insulin. It’s often linked to being overweight or inactive, or having a family history of type 2 diabetes.” That’s how NHS choices describes the most common type of diabetes while the same website26 describes the less common type as, “Type 1 diabetes is an autoimmune condition. Your immune system (the body’s natural defense against infection and illness) mistakes the cells in your pancreas as harmful and attacks them, destroying them completely or damaging them enough to stop them producing insulin. It’s not known exactly what triggers the immune system to do this, but some researchers have suggested that it may be due to a viral infection.” In its more slowly progressive form, type 1 diabetes might also be referred to as Latent Autoimmune Diabetes in Adults (LADA). The important point here is that final sentence that the triggers that cause type 1 diabetes are not known; so there is plenty of opportunity to better understand something that is not currently fully understood. However, not only is diabetes a lifelong and potentially life limiting condition but also, if poorly managed, it will drive a number of complications that each come with their own negative impacts on a patient’s life and wellbeing. Medical News Today27 lists eighteen such complications which can be shortened to: • Cardiovascular disease; • Nerve damage (neuropathy); • Kidney damage (nephropathy); • Eye damage (retinopathy); • Foot damage; • Skin conditions; • Hearing impairment; • Alzheimer’s disease.
Stages of diabetes As with most health issues, diabetes progresses through a number of stages which Gordon C. Weir and Susan Bonner-Weir helpfully categorized 12 |WWW.HOSPITALREPORTS.EU
for the American Diabetes Association28 - “Stage 1 is compensation: insulin secretion increases to maintain normoglycemia in the face of insulin resistance and/or decreasing β-cell mass. This stage is characterized by maintenance of differentiated function with intact acute glucose-stimulated insulin secretion (GSIS). Stage 2 occurs when glucose levels start to rise, reaching ~5.0–6.5 mmol/l; this is a stable state of β-cell adaptation with loss of β-cell mass and disruption of function as evidenced by diminished GSIS and β-cell dedifferentiation. Stage 3 is a transient unstable period of early decompensation in which glucose levels rise relatively rapidly to the frank diabetes of stage 4, which is characterized as stable decompensation with more severe β-cell dedifferentiation. Finally, stage 5 is characterized by severe decompensation representing a profound reduction in β-cell mass with progression to ketosis. Movement across stages 1–4 can be in either direction. For example, individuals with treated type 2 diabetes can move from stage 4 to stage 1 or stage 2. For type 1 diabetes, as remission develops, progression from stage 4 to stage 2 is typically found. Delineation of these stages provides insight into the pathophysiology of both progression and remission of diabetes.” I reproduce the full description as it is both comprehensive and succinct.
Evolving requirements for C-peptide assays and testing The same American Diabetes Association addresses the issue of laboratory analysis in diabetes diagnosis and management, which looks at, among other things, the role of C-peptide29. With better understanding of diabetes and of the various types as well as the co-morbidities and complications, a more sophisticated assay than simply age and/or a partial or total loss of insulin is required. C-peptide assays are more able to fulfil that role, being able to discern more than just the fact that a patient has diabetes – see Peter Dunwell’s article above.
SPECIAL REPORT: IMPROVING THE DIAGNOSIS AND MANAGEMENT OF DIABETES
The difference is the system VITROS® Systems ensure consistent, reliable results - the first time. Every VITROS® System is backed by Ortho’s
Looking to the Future Nothing stands still and that is certainly true for the diagnosis and treatment of diabetes. So, to finish this Report, we’ll take a brief look at some programs that seek to address this growing healthcare challenge.
Prevention is the best Given that some type 2 diabetes cases can be related to lifestyle issues, BMJ Journal reported on the 2015 Melbourne Diabetes Prevention Study30 that, in the face of projections that the world’s population suffering from diabetes could rise from an estimated 382 million in 2015 to 592 million in 25 years’ time, prevention would be a good first step, “Effective prevention is critical to reduce this looming burden of disease. In the randomized controlled setting, efficacy has been shown for lifestyle interventions, with progression to type 2 diabetes mellitus (T2DM) reduced by up to 58%, and with beneficial effects evident at 13 years follow-up” A similar 2006 program had achieved almost identical results when, University of Pittsburgh ‘Diabetes Prevention Support Center’ established a lifestyle intervention group in which, “those receiving intensive counseling on effective diet, exercise, and behavior modification, reduced their risk of developing diabetes by 58%.”
Looking for new treatments Science Alert 31 catalogues a number of treatments and management techniques on which scientists have been working, including:
• I nsulin producing implants made from stem cells; • Brand new beta cells; • A common blood pressure medication that might be helpful in treating diabetes; • A transplant of insulin-producing cells into the stomach cavity; • An extreme diet that could put type 2 diabetes into remission; • Glucose-monitoring contact lenses. Diabetes UK32 funds research projects aiming to better treat, manage or even cure diabetes. Projects include, development of an artificial pancreas and a vaccine (Type 1 diabetes), plus further understanding of genetic mechanisms and a very low-calorie diet (Type 2 diabetes). Beyond that, there is a Research Project Directory linking from the same page.
Best-in-Class Service.
We take diabetes personally
Summary These research projects might well lead to significant breakthroughs, but much of the steady improvement in outcomes for patients with diabetes results from clinicians being able to have a better understanding of each individual case (see C-peptide testing elsewhere in this Report) and a steadily improving management of each case to prevent further deterioration and, with type 2 diabetes, to possibly reduce or wholly reverse the condition. Given the projected growth in diabetes rates, any improvement in the quality and accuracy of its diagnosis and/or efficacy of its treatment cannot come fast enough for patients or healthcare systems. PR-04049
ORTHOCLINICALDIAGNOSTICS.COM
WWW.HOSPITALREPORTS.EU| 13
SPECIAL REPORT: IMPROVING THE DIAGNOSIS AND MANAGEMENT OF DIABETES
References: Diabetes UK www.diabetes.org.uk/diabetes-the-basics
1
2
Diabetes.co.uk www.diabetes.co.uk/The-big-three-diabetes-signs-and-symptoms.html
3
CBS News www.cbsnews.com/news/type-2-diabetes-early-symptoms-easy-to-miss/
4
Diabetes UK www.diabetes.org.uk/diabetes-the-basics/what-is-type-2-diabetes
5
Full Fact fullfact.org/health/diagnosis-unknown-how-many-diabetes-cases-go-undetected/
6
WHO www.euro.who.int/en/health-topics/noncommunicable-diseases/diabetes/data-and-statistics
7
Diabetes.co.uk www.diabetes.co.uk/blog/2015/08/which-country-highest-diabetes-europe/
8
Diabetes.co.uk www.diabetes.co.uk/diabetes-life-expectancy.html
9
NCBI PubMed www.ncbi.nlm.nih.gov/pubmed/17828675
10
Diabetes UK www.diabetes.org.uk/resources-s3/2017-11/diabetes%20uk%20cost%20of%20diabetes%20report.pdf
11
NHS England www.england.nhs.uk/wp-content/uploads/2016/08/impact-assessment-ndpp.pdf
12
Diabetes.co.uk www.diabetes.co.uk/diabetes-life-expectancy.html
13
Science Direct www.sciencedirect.com/science/article/pii/S1357303914002710
14
NIDDK www.niddk.nih.gov/health-information/diabetes/overview/symptoms-causes
15
Diabetes UK www.diabetes.org.uk/preventing-type-2-diabetes/diabetes-risk-factors
16
Physician’s Weekly www.physiciansweekly.com/diabetes-comorbidities-management/
17
Geographical geographical.co.uk/people/development/item/2235-the-world-at-risk
18
Medical News Today www.medicalnewstoday.com/info/diabetes
19
That Sugar Movement thatsugarmovement.com/the-importance-of-early-diagnosis-of-pre-diabetes/
20
ASPE aspe.hhs.gov/report/diabetes-national-plan-action/importance-early-diabetes-detection
21
Pritkin Longevity Center and Spa www.pritikin.com/your-health/health-benefits/diabetes/1629-diabetes-the-benefits-of-early-action.html
22
Web MD www.webmd.com/diabetes/what-is-c-peptide-test#1 dress
23
Diapedia www.diapedia.org/type-1-diabetes-mellitus/2104455111/c-peptide-in-type-1-diabetes
24
NCBI PMC www.ncbi.nlm.nih.gov/pmc/articles/PMC5446389/
25
Diabetes.co.uk www.diabetes.co.uk/treatment.html
26
NHS choices www.nhs.uk/Conditions/Diabetes-type1/Pages/Causes-old.aspx
27
Medical News Today www.medicalnewstoday.com/info/diabetes
28
American Diabetes Association diabetes.diabetesjournals.org/content/53/suppl_3/S16
29
American Diabetes Association care.diabetesjournals.org/content/34/6/e61
30
BMJ Open Diabetes Research & Care drc.bmj.com/content/3/1/e000131
31
Science Alert www.sciencealert.com/new-breakthroughs-diabetes-research-treatments-2018
32
Diabetes UK www.diabetes.org.uk/diabetes-the-basics/is-there-a-cure
14 |WWW.HOSPITALREPORTS.EU
We take diabetes personally The global impact of Diabetes is immense Ortho Clinical Diagnostics understands the growing prevalence of diabetes and is dedicated to confronting diabetes’ real impact to patient quality of life and to health care economics. Ortho’s comprehensive diabetes menu is available on VITROSŽ Immunoassay and Integrated Systems: trustworthy, reliable results, Ortho service and support, and standardized performance across the family of systems.
Please visit www.orthoclinicaldiagnostics.com PR-04048
SPECIAL REPORT: IMPROVING THE DIAGNOSIS AND MANAGEMENT OF DIABETES
Notes:
16 |WWW.HOSPITALREPORTS.EU
Hospital Reports Europe The leading specialist combined online research and networking resource for Doctors, Clinicians, Specialists, Consultants, Surgeons and other Senior Medical Professionals and Executives within both Public and Private Hospitals throughout Europe.
• Up-to-the-minute unparalleled depth of information on specialist subjects available to all site users on a free of charge open access basis. • Qualified signed up members are able to access premium content Special Reports and interact with their peers using a variety of advanced online networking tools. • Designed to help users identify new technical solutions, understand the implications of different technical choices and select the best solutions available. • Thought Leadership – Advice and guidance from internationally recognised key opinion leaders. • Peer Input – Contributions from senior healthcare professionals. • Independent editorial content – Expert and authoritative analysis from award winning journalists and leading healthcare commentators. •
Unbiased supplier-provided content.
•
Designed to facilitate debate.
•
Written to the highest professional standards.
Visit http://www.hospitalreports.eu/